Patents by Inventor Allen Comer
Allen Comer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11970818Abstract: A fibrous structure. The structure may include a plurality of continuous or semi-continuous knuckles extending from portions of the surface of the fibrous structure in a parallel path, wherein the plurality of knuckles may be separated by adjacent continuous or semi-continuous pillows. Each knuckle may comprise a plurality of discrete pillows, the plurality of discrete pillows may be arranged in a spaced configuration along the path of each knuckle; alternatively, each pillow may comprise a plurality of discrete knuckles, the plurality of discrete knuckles may be arranged in a spaced configuration along the path of each pillow.Type: GrantFiled: November 8, 2021Date of Patent: April 30, 2024Assignee: The Procter & Gamble CompanyInventors: Fei Wang, Douglas Jay Barkey, James Allen Cain, Stephen John DelVecchio, Angela Marie Leimbach, Kun Piao, James Kenneth Comer, Ryan Dominic Maladen
-
Publication number: 20220347353Abstract: The present disclosure provides methods for treating acute wounds and improving outcomes by applying to an acute wound a skin substitute that is an organotypic human skin equivalent comprising NIKS cells. In certain embodiments, the closed wound has improved vascularity, improved pigmentation, decreased thickness, decreased pain, increased pliability, increased surface area, decreased stiffness, decreased itching, improved color, or any combination thereof, as assessed by an observer or by the subject, as compared to an autograft or another skin substitute.Type: ApplicationFiled: September 28, 2020Publication date: November 3, 2022Inventors: Janice Smiell, Allen Comer, Mary Lokuta, B. Lynn Allen-Hoffmann
-
Patent number: 7955790Abstract: The present invention relates to in vitro cultured skin substitutes, and in particular to in vitro cultured skin substitutes that have improved barrier function. In some embodiments, improved barrier function is a result of improved culture conditions, while in other embodiments, improved barrier function results from genetic modification of keratinocytes. Improved culture conditions to improve barrier function include organotypic culture in the presence of linoleic acid and/or linoleic acid at about 75% humidity. Suitable genetic modifications for improving barrier function includes transfection with a DNA construct capable of expressing GKLF.Type: GrantFiled: July 16, 2008Date of Patent: June 7, 2011Assignee: Stratatech CorporationInventors: Allen Comer, Lynn Allen-Hoffmann, Michael Hoffmann
-
Patent number: 7807148Abstract: The present invention relates to in vitro cultured skin tissue, and in particular to cultured skin tissue comprising exogenous genes encoding angiogenic growth factors. In some embodiments, the keratinocytes express exogenous angiopoietin-1, HIF-1?, or a member of the VEGF family, preferably VEGF-A. In particularly preferred embodiments, the keratinocytes are incorporated into cultured skin tissue.Type: GrantFiled: May 19, 2004Date of Patent: October 5, 2010Assignee: Stratatech CorporationInventors: Allen Comer, Lynn-Allen Hoffmann
-
Publication number: 20100099576Abstract: The present invention relates to in vitro cultured skin substitutes, and in particular to in vitro cultured skin substitutes that have improved barrier function. In some embodiments, improved barrier function is a result of improved culture conditions, while in other embodiments, improved barrier function results from genetic modification of keratinocytes. Improved culture conditions to improve barrier function include organotypic culture in the presence of linoleic acid and/or linoleic acid at about 75% humidity. Suitable genetic modifications for improving barrier function includes transfection with a DNA construct capable of expressing GKLF.Type: ApplicationFiled: July 16, 2008Publication date: April 22, 2010Inventors: ALLEN COMER, LYNN ALLEN-HOFFMANN, MICHAEL HOFFMANN
-
Publication number: 20090169528Abstract: The present invention relates to in vitro cultured skin tissue, and in particular to cultured skin tissue comprising exogenous genes encoding angiogenic growth factors. In some embodiments, the keratinocytes express exogenous angiopoietin-1 or a member of the VEGF family, preferably VEGF-A. In particularly preferred embodiments, the keratinocytes are incorporated into cultured skin tissue.Type: ApplicationFiled: February 25, 2009Publication date: July 2, 2009Applicant: STRATATECH CORPORATIONInventors: Allen Comer, Michael Hoffmann, Lynn-Allen Hoffmann
-
Patent number: 7501238Abstract: The present invention relates to in vitro cultured skin substitutes, preferably to in vitro cultured skin substitutes that have improved barrier function. In particular, the present invention relates to the use of such skin substitutes for irritancy testing. The present invention provides improved methods of screening compounds for irritancy activity, as well for identifying novel irritant responsive genes.Type: GrantFiled: March 1, 2002Date of Patent: March 10, 2009Inventors: Allen Comer, Lynn Allen-Hoffmann, Michael Hoffmann
-
Patent number: 7498167Abstract: The present invention relates to in vitro cultured skin tissue, and in particular to cultured skin tissue comprising exogenous genes encoding angiogenic growth factors. In some embodiments, the keratinocytes express exogenous angiopoietin-1 or a member of the VEGF family, preferably VEGF-A. In particularly preferred embodiments, the keratinocytes are incorporated into cultured skin tissue.Type: GrantFiled: April 29, 2003Date of Patent: March 3, 2009Inventors: Allen Comer, Michael Hoffmann, Lynn-Allen Hoffmann
-
Patent number: 7407805Abstract: The present invention relates to in vitro cultured skin substitutes, and in particular to in vitro cultured skin substitutes that have improved barrier function. In some embodiments, improved barrier function is a result of improved culture conditions, while in other embodiments, improved barrier function results from genetic modification of keratinocytes. Improved culture conditions to improve barrier function include organotypic culture in the presence of linoleic acid and/or linoleic acid at about 75% humidity. Suitable genetic modifications for improving barrier function includes transfection with a DNA construct capable of expressing GKLF.Type: GrantFiled: September 27, 2005Date of Patent: August 5, 2008Inventors: Allen Comer, Lynn Allen-Hoffmann, Michael Hoffmann
-
Publication number: 20060141627Abstract: The present invention relates to expression vectors capable of promoting transgene expression. The expression vectors include site specific recombination elements, insulator elements, and recombinase elements. In particular, the present invention provides methods for obtaining specific and stable integration of nucleic acids into eukaryotic cells through site specific recombination.Type: ApplicationFiled: November 18, 2005Publication date: June 29, 2006Applicant: Stratatech CorporationInventor: Allen Comer
-
Publication number: 20060121608Abstract: The present invention relates to in vitro cultured skin substitutes, and in particular to in vitro cultured skin substitutes that have improved barrier function. In some embodiments, improved barrier function is a result of improved culture conditions, while in other embodiments, improved barrier function results from genetic modification of keratinocytes. Improved culture conditions to improve barrier function include organotypic culture in the presence of linoleic acid and/or linoleic acid at about 75% humidity. Suitable genetic modifications for improving barrier function includes transfection with a DNA construct capable of expressing GKLF.Type: ApplicationFiled: September 27, 2005Publication date: June 8, 2006Inventors: Allen Comer, Lynn Allen-Hoffmann, Michael Hoffmann
-
Patent number: 6974697Abstract: The present invention relates to in vitro cultured skin substitutes, and in particular to in vitro cultured skin substitutes that have improved barrier function. In some embodiments, improved barrier function is a result of improved culture conditions, while in other embodiments, improved barrier function results from genetic modification of keratinocytes. Improved culture conditions to improve barrier function include organotypic culture in the presence of linoleic acid and/or linoleic acid at about 75% humidity. Suitable genetic modifications for improving barrier function includes transfection with a DNA construct capable of expressing GKLF.Type: GrantFiled: March 1, 2002Date of Patent: December 13, 2005Assignee: Stratech CorporationInventors: Allen Comer, Lynn Allen-Hoffmann, Michael Hoffmann
-
Publication number: 20050164295Abstract: A method of screening for selective inhibitors or activators Smad protein function is disclosed. In one embodiment, the invention comprises the steps of (a) obtaining a phosphorylated Smad protein or protein complex, (b) allowing the phosphorylated Smad protein or complex to interact with a target protein or peptide in the presence of a test compound, and (c) analyzing the binding of the phosphorylated Smad complex or protein and the target protein or peptide, wherein a perturbation of binding indicates that the test compound is an inhibitor or activator of Smad-target protein interaction.Type: ApplicationFiled: June 11, 2002Publication date: July 28, 2005Inventors: F. Hoffmann, Allen Comer
-
Publication number: 20050013807Abstract: The present invention relates to in vitro cultured skin tissue, and in particular to cultured skin tissue comprising exogenous genes encoding angiogenic growth factors. In some embodiments, the keratinocytes express exogenous angiopoietin-1, HIF-1?, or a member of the VEGF family, preferably VEGF-A. In particularly preferred embodiments, the keratinocytes are incorporated into cultured skin tissue.Type: ApplicationFiled: May 19, 2004Publication date: January 20, 2005Applicant: Stratatech CorporationInventors: Allen Comer, Lynn-Allen Hoffmann
-
Publication number: 20040009591Abstract: The present invention relates to in vitro cultured skin tissue, and in particular to cultured skin tissue comprising exogenous genes encoding angiogenic growth factors. In some embodiments, the keratinocytes express exogenous angiopoietin-1 or a member of the VEGF family, preferably VEGF-A. In particularly preferred embodiments, the keratinocytes are incorporated into cultured skin tissue.Type: ApplicationFiled: April 29, 2003Publication date: January 15, 2004Applicant: Stratatech CorporationInventors: Allen Comer, Michael Hoffmann, Lynn-Allen Hoffmann
-
Publication number: 20020187498Abstract: The present invention relates to in vitro cultured skin substitutes, preferably to in vitro cultured skin substitutes that have improved barrier function. In particular, the present invention relates to the use of such skin substitutes for irritancy testing. The present invention provides improved methods of screening compounds for irritancy activity, as well for identifying novel irritant responsive genes.Type: ApplicationFiled: March 1, 2002Publication date: December 12, 2002Inventors: Allen Comer, Lynn Allen-Hoffmann, Michael Hoffmann
-
Publication number: 20020168768Abstract: The present invention relates to in vitro cultured skin substitutes, and in particular to in vitro cultured skin substitutes that have improved barrier function. In some embodiments, improved barrier function is a result of improved culture conditions, while in other embodiments, improved barrier function results from genetic modification of keratinocytes. Improved culture conditions to improve barrier function include organotypic culture in the presence of linoleic acid and/or linoleic acid at about 75% humidity. Suitable genetic modifications for improving barrier function includes transfection with a DNA construct capable of expressing GKLF.Type: ApplicationFiled: March 1, 2002Publication date: November 14, 2002Inventors: Allen Comer, Lynn Allen-Hoffmann, Michael Hoffmann